Genprex rakes in $8M in at-the-market stock offering – Proactive Investors USA & Canada

Posted: January 23, 2020 at 12:49 pm

The gene therapy company sold 7.6 million shares of stock at a price of $1.05 per share

Genprex Inc () announced an $8 million offering of stock through securities purchase agreements made with influential investors.

The gene therapy company sold 7.6 million shares at a price of $1.05 per share, in accordance with Nasdaq rules governing registered direct offerings.

Genprex, based in Austin, Texas and Cambridge, Massachusetts, plans to use the proceeds to advance its clinical programs in non-small cell lung cancer, as well as for working capital and general corporate purposes.

The company is developing a new approach to treating cancer, including its initial product candidateOncoprex, which is an immunogene therapy for non-small cell lung cancer.

Contact Andrew Kessel at [emailprotected]

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

Go here to see the original:
Genprex rakes in $8M in at-the-market stock offering - Proactive Investors USA & Canada

Related Post

Comments are closed.

Archives